172 related articles for article (PubMed ID: 38195475)
21. The Expression Level of
Masuda T; Noda M; Kitagawa A; Hu Q; Fujii A; Ito S; Kosai K; Ando Y; Matsumoto Y; Ohtsu H; Uchida H; Ohno S; Mimori K
Anticancer Res; 2020 Jul; 40(7):3733-3742. PubMed ID: 32620612
[TBL] [Abstract][Full Text] [Related]
22. MDR1-EXPRESSING CD4
Di Roio A; Hubert M; Besson L; Bossennec M; Rodriguez C; Grinberg-Bleyer Y; Lalle G; Moudombi L; Schneider R; Degletagne C; Treilleux I; Campbell DJ; Metzger S; Duhen T; Trédan O; Caux C; Ménétrier-Caux C
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37940345
[TBL] [Abstract][Full Text] [Related]
23. Predictive and Prognostic Role of Peripheral Blood T-Cell Subsets in Triple-Negative Breast Cancer.
Li M; Xu J; Jiang C; Zhang J; Sun T
Front Oncol; 2022; 12():842705. PubMed ID: 35242718
[TBL] [Abstract][Full Text] [Related]
24. Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors.
Guo H; Ding Q; Gong Y; Gilcrease MZ; Zhao M; Zhao J; Sui D; Wu Y; Chen H; Liu H; Zhang J; Resetkova E; Moulder SL; Wang WL; Huo L
Breast Cancer Res; 2020 Jun; 22(1):69. PubMed ID: 32576238
[TBL] [Abstract][Full Text] [Related]
25. The PD-1/PD-L1 Inhibitory Pathway is Altered in Primary Glomerulonephritides.
Grywalska E; Smarz-Widelska I; Krasowska-Zajac E; Korona-Glowniak I; Zaluska-Patel K; Mielnik M; Podgajna M; Malm A; Rolinski J; Zaluska W
Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):133-143. PubMed ID: 28770269
[TBL] [Abstract][Full Text] [Related]
26. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
Yan Y; Wang X; Liu C; Jia J
BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
[TBL] [Abstract][Full Text] [Related]
27. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
[TBL] [Abstract][Full Text] [Related]
28. The characteristic profiles of PD-1 and PD-L1 expressions and dynamic changes during treatment in active tuberculosis.
Shen L; Shi H; Gao Y; Ou Q; Liu Q; Liu Y; Wu J; Zhang W; Fan L; Shao L
Tuberculosis (Edinb); 2016 Dec; 101():146-150. PubMed ID: 27865385
[TBL] [Abstract][Full Text] [Related]
29. Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial.
Pelekanou V; Barlow WE; Nahleh ZA; Wasserman B; Lo YC; von Wahlde MK; Hayes D; Hortobagyi GN; Gralow J; Tripathy D; Porter P; Szekely B; Hatzis C; Rimm DL; Pusztai L
Mol Cancer Ther; 2018 Jun; 17(6):1324-1331. PubMed ID: 29588392
[TBL] [Abstract][Full Text] [Related]
30. PD-L1
Zacca ER; Onofrio LI; Acosta CDV; Ferrero PV; Alonso SM; Ramello MC; Mussano E; Onetti L; Cadile II; Stancich MI; Taboada Bonfanti MC; Montes CL; Acosta Rodríguez EV; Gruppi A
Front Immunol; 2018; 9():2241. PubMed ID: 30327652
[No Abstract] [Full Text] [Related]
31. PD-1 and PD-L1 Expression in Peripheral CD4/CD8+ T Cells Is Restored in the Partial Remission Phase in Type 1 Diabetes.
Li X; Zhong T; Tang R; Wu C; Xie Y; Liu F; Zhou Z
J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32236416
[TBL] [Abstract][Full Text] [Related]
32. Aberrant Alteration of Circulating Lymphocyte Subsets in Small Cell Lung Cancer Patients Treated with Radiotherapy.
Li H; Yu H; Lan S; Zhao D; Liu Y; Cheng Y
Technol Cancer Res Treat; 2021; 20():15330338211039948. PubMed ID: 34851203
[No Abstract] [Full Text] [Related]
33. Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients.
Formenti SC; Hawtin RE; Dixit N; Evensen E; Lee P; Goldberg JD; Li X; Vanpouille-Box C; Schaue D; McBride WH; Demaria S
J Immunother Cancer; 2019 Jul; 7(1):177. PubMed ID: 31296256
[TBL] [Abstract][Full Text] [Related]
34. Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression.
Van Berckelaer C; Rypens C; van Dam P; Pouillon L; Parizel M; Schats KA; Kockx M; Tjalma WAA; Vermeulen P; van Laere S; Bertucci F; Colpaert C; Dirix L
Breast Cancer Res; 2019 Feb; 21(1):28. PubMed ID: 30777104
[TBL] [Abstract][Full Text] [Related]
35. Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial.
Graeser M; Feuerhake F; Gluz O; Volk V; Hauptmann M; Jozwiak K; Christgen M; Kuemmel S; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kolberg-Liedtke C; Kates R; Wuerstlein R; Nitz U; Kreipe HH; Harbeck N
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963012
[TBL] [Abstract][Full Text] [Related]
36. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
[No Abstract] [Full Text] [Related]
37. Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy.
Murta EF; de Andrade JM; Falcão RP; Bighetti S
Tumori; 2000; 86(5):403-7. PubMed ID: 11130570
[TBL] [Abstract][Full Text] [Related]
38. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy.
Ghebeh H; Barhoush E; Tulbah A; Elkum N; Al-Tweigeri T; Dermime S
BMC Cancer; 2008 Feb; 8():57. PubMed ID: 18294387
[TBL] [Abstract][Full Text] [Related]
39. PD-L1 expression and infiltration by CD4
Lee HJ; Shin DH; Lee YJ; Lee SJ; Hwang CS; Kim A; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Park SW
Histopathology; 2020 Apr; 76(5):714-721. PubMed ID: 31841221
[TBL] [Abstract][Full Text] [Related]
40. Expression of PD-L1 in Locally Advanced Breast Cancer and Its Impact on Neoadjuvant Chemotherapy Response.
Hussein MA; Ismail HA; Sakr M; Nouh MA
Asian Pac J Cancer Prev; 2022 Jun; 23(6):2095-2103. PubMed ID: 35763653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
